A/Prof Liz Caldon

A/Prof Liz Caldon

A/Prof Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer, basal-like breast cancers and ovarian cancers.  Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they

Research Level

Lab Head

Biography

A/Prof Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer, basal-like breast cancers and ovarian cancers.  Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease.
Liz is a Cancer Institute NSW Fellow, and a recipient of the Mavis Robertson fellowship from the NBCF. She is an Associate Editor for the journals Frontiers in Cell and Developmental Biology and Endocrine Oncology. 
A/Prof Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer, basal-like breast cancers and ovarian cancers.  Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease.
Liz is a Cancer Institute NSW Fellow, and a recipient of the Mavis Robertson fellowship from the NBCF. She is an Associate Editor for the journals Frontiers in Cell and Developmental Biology and Endocrine Oncology. 

Awards and Honours

2021-2024 Cancer Institute NSW Fellowship
2021-2023 Mavis Robertson NBCF Fellowship
2018 - The Ridley Ken Davies Award
2017 - Heliflite Young Explorer Award
2017-2020 National Breast Cancer Foundation Career Development Fellowship
2015 - CHAMP Private Equity Young Pioneer Award
2014 - Cancer Institute Career Development Fellowship
2013 - Cure Cancer Conference and Professional Development Grant
2013 - “Best Translational Research Presentation”, Lowy Cancer Symposium, UNSW, Sydney, Australia
2011-2016 - National Breast Cancer Foundation Postdoctoral Fellowship
2011 - Cure Cancer Australia Postdoctoral Fellowship
2010 - Young Garvan Fellowship
2009 - Qantas Research Travel Award
2005-2007 - Cancer Institute NSW Scholar
2004 - Beth Yarrow Scholarship
2003 - LH Ainsworth Scholarship in Cancer Research
2002 - Connaught Graduate Fellowship, University of Toronto

Education

2007 - PhD, University of NSW, Sydney - Australia
2003 - MSc University of Toronto - Canada
2001 - Bachelor of Laws (LLB), University of New South Wales, Sydney - Australia
1998 - BSc (Hons, University Medal) University of New South Wales, Sydney - Australia

Fundings

The amazing organisations that make our research possible are:

  • NBCF (IIRS Grants)
  • Cancer Institute NSW
  • NHMRC (Project Grant)
  • Sphere CAG
  • Tour de Cure
  • Perpetual Impact
  • Mostyn Foundation

Our group also receives valuable input from consumer representatives, and we are grateful to Cancer Voices NSW and BCNA for their support in connecting us with the community. 

Selected Publications

  1. Diar Aziz, Christine Lee, Venessa Chin, Zoe Phan, Kristine Fernandez, kConFab Investigators, AOCS, Paul Waring, CE Caldon “High cyclin E1 protein, but not gene amplification, is prognostic for basal‐like breast cancer” (2022) Journal of Pathology: Clinical Research https://doi.org/10.1002/cjp2.269
  2. Jahan, Z., Benthani, F.A., Currey, N., Parker, H.W., Dahlstrom, J.E., Caldon, C.E., Kohonen-Corish, M.R.J. “MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib.” (2022) Cancers14, 2859. https://doi.org/10.3390/cancers14122859
  3. Holliday, H., J. Yang, E. Dodson, I. Nikolic, A. Kamili, M. Wheatley, N. Deng, S. Alexandrou, T. P. Davis, M. Kavallaris, E. Caldon, J. McCarroll, K. De Preter, P. Mestdagh, G. M. Marshall, K. J. Simpson, J. Fletcher and A. Swarbrick (2022). "miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma." Molecular Therapy 30(3): 1119-1134.
  4. Qian Du; Grady C Smith; Phuc Loi Luu; James M Ferguson; Nicola J Armstrong; C Elizabeth Caldon; Elyssa Campbell; Shalima S Nair; Elena Zotenko; Cathryn M Gould; Michael Buckley; Kee-Ming Chia; Neil Portman; Elgene Lim; Dominik Kaczorowski; Chia-Ling Chan; Kirston Barton; Ira W Deveson; Martin A Smith; Joseph E Powell; Ksenia Skvortsova; Clare Stirzaker; Joanna Achinger-Kawecka; Susan Joy Clark (2021) “DNA methylation is required to maintain both DNA replication timing precision and 3D genome integrity” Cell Reports 36 (12), 109722
  5. Kendelle J. Murphy, Daniel A. Reed, Claire Vennin, James R.W. Conway, Max Nobis Julia Yin, Cecilia R Chambers, Brooke A Pereira, Victoria Lee, Elysse C Filipe, Morghan C. Lucas, Sean C. Warren, Joanna N. Skhinas, Astrid Magenau, Xanthe L. Metcalf, Janett Stoehr, Gretel Major, Ashleigh Parkin, Romain Bidanel, Anaiis Zaratzian, Andrew Da Silva, Lea Abdulkhalek, Australian Pancreatic Genome Initiative (APGI), Anthony J Gill , Amber L. Johns, Andrew V Biankin, Jaswinder Samra, Angela Chou, Andrew Burgess, Elizabeth Caldon, Lisa Horvath, Roger Daly, Nikolaj Gadegaard, Yingxiao Wang, Owen J. Sansom, Jennifer P. Morton, Thomas R. Cox Marina Pajic, David Herrmann,# and Paul Timpson#. (2021) “Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status” Science Advances 7 (40) eabh0363
  6. D Aziz, N Portman, KJ Fernandez, C Lee, S Alexandrou, A Llop-Guevara, Z Phan, A Yong, A Wilkinson, C Sergio, D Ferraro, D Etemadmoghadam, D Bowtell, kConFab Investigators, V Serra, P Waring, E Lim, CE Caldon (2021) “Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors” npj Breast Cancer 7 (1), 1-14
  7. Floerchinger A#, Murphy KJ#, Warren SC, McCulloch AT, Lee YK, Stoehr J, Melenec P, Guaman CS, Latham SL, Metcalf X, Lee V, Rolo S, Sultani G, McDonald L, Mason SM, Ferrari N, Johnsson A-KE, Sansom OJ, Morton JP, Welch HCE, Blyth K, Caldon CE, Herrmann D, Anderson KI, Timpson P*, Nobis M*. (2021)“Optimizing Metastatic Cascade Dependent Rac1 Targeting in Breast Cancer: target validation and guidance using Optical Window Intravital FRET imaging” Cell Reports 36 (11), 109689
  8. Hickey, Theresa E., Luke A. Selth, Kee Ming Chia, Geraldine Laven-Law, Heloisa H. Milioli, Daniel Roden, Shalini Jindal, Mun Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen N. Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C. Elizabeth Caldon, Tarek M. Abdel-Fatah, Ian O. Ellis, Wilbert Zwart, Carlo Palmieri, Carol A. Sartorius, Alex Swarbrick, Elgene Lim, Jason S. Carroll, and Wayne D. Tilley. 2021. 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27: 310-20.
  9. C Lee, K Fernandez, S Alexandrou, CM Sergio, N Deng, S Rogers, A Burgess, CE Caldon (2020) “Cyclin E2 promotes whole genome doubling in breast cancer” Cancers 12, 2268.
  10. A Burgess*, CE Caldon* (2020) “Proceedings from ACCM19: Cell Cycle, DNA Damage Response and Telomeres” Frontiers in Cell and Developmental Biology 8, 805 *co-senior
  11. N Portman, HH Milioli, S Alexandrou, R Coulson, A Yong, KJ Fernandez, KM Chia, E Halilovic, D Segara, A Parker, S Haupt, Y Haupt, W Tilley, A Swarbrick, CE Caldon*, E Lim* (2020) “MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer” Breast Cancer Research 22 (1), 1-17 *co-senior
  12. CE Caldon (2020) “Friends and foes: our evolving understanding of the link between Fbxw7 and p53 in cancer” Neoplasia 22 (11), 659
  13. HH Milioli, S Alexandrou, E Lim, CE Caldon (2020)“Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets” Endocrine-Related Cancer 27 (5), R93-R112
  14. J Achinger-Kawecka, F Valdes Mora, P Luu, K Giles, CE Caldon, W Qu, S Nair, S Soto, W Locke, N Yeo-Teh, C Gould, Q Du, G Smith, I Ramos, K Fernandez, D Hoon, J Gee, C Stirzaker and S Clark (2020) “Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer” Nature Communications 11 (1), 1-17
  15. S Tadesse, A Anshabo, N Portman, E Lim, W Tilley, CE Caldon* and S Wang* (2020) “Targeting CDK2 in cancer: challenges and opportunities for therapy” Drug Discovery Today 25 (2), 406-413 *Co-senior
  16. CE Caldon, A Burgess (2019) “Label Free, Quantitative Single-Cell Fate Tracking of Time-Lapse Movies” MethodsX, 6, 2468-2475
  17. Q Du*, SA Bert*, NJ Armstrong, CE Caldon, J Song, S Nair, CM Gould, P Loi Luu, T Peters, A Khoury, W Qu, E Zotenko, C Stirzaker, SJ Clark (2019) “DNA replication timing in concert with epigenome remodelling is associated with the nature of chromosomal rearrangements in cancer “ Nature Communications 10 (1), 1-15 *Equal contribution
  18. Tadesse S, CE Caldon, W Tilley and S Wang (2019) "Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update" Journal of Medicinal Chemistry 62 (9), 4233-4251
  19. Chia K, Milioli H, Portman, N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley W, Hickey T, & Lim E (2019) “Non-canonical AR activity facilitates endocrine resistance in breast cancer”, Endocrine-Related Cancer, 26(2), 251-264
  20. Portman, N, Alexandrou, S, Carr, E, Wang, S, Lim, E, CE Caldon (2019) “Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer” Endocrine Related Cancer 26 (1), R15-R30
  21. Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP*, Timpson P* (2018) “Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer” Cell Reports 23(11):3312-26 *Co-senior
  22. Rogers, S, R A McCloy, BL Parker, D Gallego-Ortega, AMK Law, VT Chin, JRW Conway, D Fey, E Millar, S O’Toole, N Deng, A Swarbrick, P Chastain, A Cesare, P Timpson, CE Caldon, DE James, DN Watkins and A Burgess (2018) "MASTL overexpression promotes chromosome instability and metastasis in breast cancer" Oncogene 37:4518–4533
  23. Aziz, D, D Etemadmoghadam,* CE Caldon,* G Au-Yeung, N Deng, R Hutchinson, D Bowtell, P Waring and AOCS Group (2018) "19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes" Gynecologic Oncology 151 (2), 327-336 *Equal contribution
  24. Caldon, CE (2016) “Cdk2 regulates metastasis suppressor Brms1” Cell Cycle, i15(6): 779-780
  25. S Rogers, D Fey, RA McCloy, BL Parker, NJ Mitchell, RJ Payne, RJ Daly, DE James, CE Caldon, DN Watkins, DR Croucher, and A Burgess (2016) “PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells” Journal of Cell Science 129(7) 1340-1354
  26. Rogers, S, BS Gloss, CS Lee, CM Sergio, ME Dinger, EA Musgrove, A Burgess, CE Caldon (2015) “Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells” Cell Division 10 (1), 1
  27. Loh, SW, Cooper, C, Selinger, CI, Barnes, E, Chan, C, Carmalt, H, West, R, Gluch, L, Beith, JM, Caldon, CE, O'Toole, S (2015) “Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast” Journal of Clinical Pathology jclinpath-2014-202331
  28. Caldon, CE (2014) “Estrogen signalling and the DNA damage response in hormone dependent breast cancers” Frontiers in Oncology 4:106
  29. McCloy RA, S Rogers, CE Caldon, T Lorca, A Castro, A Burgess (2014) “Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events” Cell Cycle 13 (9), 0-1
  30. A Stone, MJ Cowley, F Valdes-Mora, RA McCloy, CM Sergio, D Gallego-Ortega, CE Caldon, CJ Ormandy, AV Biankin, JM Gee, RI Nicholson, CG Print, SJ Clark, EA Musgrove (2013) “BCL-2 hypermethylation is a potential biomarker of sensitivity to anti-mitotic chemotherapy in endocrine-resistant breast cancer” Molecular Cancer Therapeutics 12 (9), 1874-1885
  31. Caldon CE, CM Sergio, A Burgess, AJ Deans, RL Sutherland, EA Musgrove (2013) “Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1” Cell Cycle 12(4):606-17
  32. Caldon CE*, CM Sergio, RL Sutherland, EA Musgrove (2013) “Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells” Cell Cycle 12(4):596-605 *Corresponding author
  33. Caldon CE, C M Sergio, J Kang, A Muthukaruppan, M N Boersma, A Stone, J Barraclough, C S Lee, M A Black, L D Miller, J M Gee, R I Nicholson, R L Sutherland, C G Print and E A Musgrove (2012) "Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells" Molecular Cancer Therapeutics 11(7): 1488-1499
  34. Musgrove, E A, CE Caldon, J Barraclough, A Stone and R L Sutherland (2011) "Cyclin D as a therapeutic target in cancer" Nature Reviews Cancer 11(8): 558-572
  35. Caldon CE, R L Sutherland and E A Musgrove (2010) "Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer" Cell Cycle 9: 10
  36. Caldon CE and E A Musgrove (2010) "Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer" Cell Division 5(2)
  37. Caldon CE, C M Sergio, J Schutte, M N Boersma, R L Sutherland, J S Carroll and E A Musgrove (2009) "Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc" Molecular and Cellular Biology 29(17): 4623-4639
  38. Caldon CE, A Swarbrick, C S Lee, R L Sutherland and E A Musgrove (2008) "The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini" Cancer Research 68(8): 3026-3036
  39. Caldon CE, C S Lee, R L Sutherland and E A Musgrove (2008) "Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation" Oncogene 27(1): 126-138
  40. Caldon CE, R J Daly, R L Sutherland and E A Musgrove (2006) "Cell cycle control in breast cancer cells" Journal of Cellular Biochemistry 97(2): 261-274